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ABSTRACT 
Background: Crescentic glomerulonephritis represents the extreme end on the spectrum of glomerular 
injury. It can result from a wide range of disease conditions and clinically is marked by a rapid 
deterioration in renal function over days, weeks or months. Although rare, crescentic 
glomerulonephritis is an important entity to recognize because prompt treatment can improve patient 
outcomes significantly. Literature on the prevalence, clinical presentation, aetiology and outcome of 
histologically proven crescentic glomerulonephritis among children, in Africa, is scanty. Most of what 
is known about this entity is extrapolated from adult studies and from paediatric studies that have for 
the most part been conducted outside the African continent. 
Objective: This study was conducted in order to determine the incidence, clinical presentation, 
aetiology and outcome of histologically proven crescentic glomerulonephritis in children presenting to 
the Red Cross Children’s Hospital, Cape Town, South Africa. 
Methods: This was a retrospective folder review in which the renal biopsy records of children less than 
18 years old who had had native kidney biopsies performed between 2004 and July 2015 at the Red 
Cross Children’s Hospital were reviewed. The clinical notes of patients found to have been diagnosed 
with crescentic glomerulonephritis were traced so as to extract demographic and clinical information 
which was then recorded onto the study data sheet. No attempt to contact patients or their families was 
made. Data analysis with regard to the incidence, the clinical features and the outcome of crescentic 
glomerulonephritis was done using SPSS version 22. 
Results:  A total of 470 native kidney biopsies were performed in the period under review. Of these, 24 
had crescentic glomerulonephritis, accounting for an incidence of 5.1 %. The sub-types of crescentic 
glomerulonephritis were immune-complex in 19 (80%), Pauci-immune in 2 (8 %), unspecified type in 
3 (12 %) and no child had the anti-glomerular basement membrane subtype. The underlying aetiology 
of the immune complex sub-type was post-infectious in 11(57.9%), idiopathic in 4(21%), HSP/IgA 
nephropathy in 2 (10.5%), SLE in 1 (5.3%) and mesangiocapillary glomerulonephritis in 1(5.3%). 
Fourteen of the subjects were male thus giving a male to female ratio of 1.4 while the mean age of the 
children was 8.3 [range- 1 to 14 years]. The commonest clinical features were hypertension (90%), 
nephrotic range proteinuria (80%), macroscopic haematuria (57%), oedema (94%) and anaemia (88%). 
None of these had a statistically significant association to the renal outcome. Ten (77%) out of the 13 
children with crescentic glomerulonephritis who were followed up for more than a year were found to 
have either died, had residual renal dysfunction or been transplanted at the last clinical contact.  
Conclusion: Crescentic glomerulonephritis was diagnosed in 5.1% of paediatric native renal biopsies 
which is consistent with what has been reported elsewhere. Unlike reports from other geographical 
areas the vast majority (80%) of the cases had immune-complex glomerulonephritis with a suspected 
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post-infectious aetiology in over half of these. Similar to earlier reports from South Africa the outcome 
was poor in most (77%) of the patients. Further research is required to characterise the factors that make 
post-infectious glomerulonephritis particularly severe in this population. 
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CHAPTER 1: INTRODUCTION 
 
1.0. Preamble  
Crescentic glomerulonephritis is a severe form of glomerulonephritis that is marked on histology by an 
extra-capillary proliferation in Bowman’s space, and can result from a vast array of disease 
conditions(1). It is a non-specific marker of severe glomerular injury and characteristically presents 
with a rapid deterioration in renal function over days, weeks or months(2). The ensuing renal damage 
is often severe, irreversible and unrelenting and will often result into chronic kidney disease and death 
particularly if left untreated(3). The resulting chronic kidney disease has a devastating effect on the 
growth and development of children and places a heavy drain on health system resources to provide the 
expensive therapies that are required for its management(4, 5). This burden is especially felt in regions 
of the world with limited resources such as Africa. Data on the aetiology, clinical features, outcome and 
factors that may modify outcome in crescentic glomerulonephritis in children, particularly from the 
African continent is scanty. Admittedly crescentic glomerulonephritis only affects a small proportion 
of children with estimates that it only comprises about eleven percent of unselected renal biopsies in 
children and that the accompanying clinical syndrome has an incidence of only 7 cases per million 
population per year (2, 6, 7). Yet because of the associated severe glomerular injury and the potential 
devastating renal dysfunction it becomes an important disease for clinicians to recognise. This is 
particularly so because it is known that the associated deterioration in renal function may be ameliorated 
by prompt and appropriate therapy administered in the early stages of the disease(8).  
1.1 Structure of normal the glomerulus 
The basic functional unit of the kidney is the nephron which consists of two parts: the glomerulus and 
the tubular segment. The glomerulus is the filtration unit and consists of a tuft of capillaries and matrix 
that are contained in the proximal part of the tubule: the Bowman’s capsule. It consists of three main 
cell types: fenestrated endothelial cells, mesangial cells and podocytes. The endothelial cells and 
podocytes are separated by a basement membrane and together they form the filtration barrier. This 
filtration barrier acts to prevent cellular components of blood, proteins and other molecules from 
passing into the ultrafiltrate in Bowman’s space. The passage of molecules is regulated in part due to 
limits set by charge and size(9). Various factors such as inflammation can disrupt the normal function 
of this barrier. Figure 1 below illustrates a microgram of a normal glomerulus while figure 2 is a 
schematic representation of the constituents of the filtration barrier. 
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Figure 1. Micrograph of Normal Glomerulus-courtesy of Dr Luchenga Muchelenganga, University 
of Zambia 
 
 
 
 
        Fenestrated  
     Endothelial cell  
 
 
 
 
 
                                                                            Foot process of podocyte    
      
                Glomerular basement membrane 
Figure 2. Simplified illustration of components of the glomerular filtration barrier 
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1.3 Glomerular extra-capillary proliferation 
Many of the processes responsible for crescentic glomerulonephritis are immune based(1). These can 
result from many disease conditions. During inflammation leukocytes are attracted to the site of 
inflammation or injury by cytokines during the process of chemotaxis. Leukocytes undergo margination 
due to the interaction of various adhesion molecules expressed on their surfaces as well as on endothelial 
cell surfaces and eventually leave the capillary lumen by diapedesis. At the site of deposition of immune 
complexes the neutrophils are activated to go through the respiratory burst and to release the contents 
of their toxic granules such as proteinases. These together with reactive oxygen species cause damage 
to the extracellular matrix in the glomerular basement membrane thus breaching the filtration barrier.  
In addition there is further production of inflammatory cytokines which among other things enhance 
the migration of inflammatory cells as well as induce the adaptive arm of the immune system(10). 
If the damage to the extracellular matrix is severe then a breach in the filtration barrier occurs with 
coagulation proteins, macrophages, neutrophils spilling into bowman’s space. This exudate also 
contains factors that stimulate the visceral and parietal cells to begin to proliferate resulting into a 
multilayer of cells which encroach into bowman’s space. This is referred to as an extra capillary 
proliferation. The resulting lesion is shaped like a crescent hence the term crescentic (1). By convention 
a crescent must have at least two layers of cells in Bowman’s space. Figure 3 is a micrograph of a 
glomerular crescent. 
 
Figure 3. A glomerular crescent-courtesy of A/prof Pillay, University of Cape Town  (11) 
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1.4 Crescentic glomerulonephritis 
By convention when  more than 50% of glomeruli exhibit crescents this is referred to as  crescentic 
glomerulonephritis(1). There are three sub-groups: type I is anti-glomerular basement disease, Type II 
is immune-complex crescentic glomerulonephritis and type III is Pauci-immune or Anti neutrophil 
cytoplasmic antibody associated glomerulonephritis(3). These are differentiated based on 
immunofluorescence findings on biopsy and also serological findings. This is illustrated in table 1 
below. 
Table 1. Categorization of crescentic glomerulonephritis 
Sub-type Immunofluorescence  Serology  
I-Anti glomerular basement disease Linear  Anti – glomerular basement antibodies 
II- Immune- complex  Granular Various depending on aetiology 
 e.g. SLE markers 
III- Pauci-immune < 2+ immune globulin deposition 
,scanty 
80-90% ANCA 
 
Various factors such as geography, sex, age, ethnicity and level of industrialization may influence the 
epidemiology of these subtypes(1). There is no clear indication from the literature on what the profile 
of crescentic glomerulonephritis in the paediatric age group is in the South African population but 
earlier series in adults predominantly and a few small series in children seem to suggest that a post 
infectious aetiology is predominant particularly in black children (12-14). 
Crescentic glomerulonephritis usually presents with a rapid deterioration in renal function with children 
often presenting with haematuria, oliguria and fluid over load(3). This type of clinical presentation is 
called rapidly progressive glomerulonephritis. While it occurs often with crescentic glomerulonephritis 
it is not necessarily synonymous with it(2). 
The outcome is reported as poor in about half of the cases particularly if post infectious. Treatment with 
immune suppression has been shown to improve outcome if instituted early. Thus one could say that 
potentially, crescentic glomerulonephritis is a preventable or treatable cause of chronic kidney disease 
albeit in only a small group of patients. 
 
1.6 statement of the problem 
 As stated above, numerous studies have demonstrated that crescentic glomerulonephritis is not 
pathognomonic of any disease and can occur in a wide spectrum of disease conditions. It is known that 
the relative importance of each of these disease conditions varies with age, ethnicity and geography (2). 
17 
 
Most of these studies however have been conducted outside Africa and largely in small series. As such 
there is a paucity of data on the predominant clinical presentation, the spectrum of diseases associated 
with crescentic glomerulonephritis and also the patient outcomes with regards to renal function and 
patient survival in an African setting. This is particularly so in the paediatric age group. 
We retrospectively reviewed the records of all children with a diagnosis of crescentic 
glomerulonephritis in their native kidney biopsies presenting to the Red Cross War Memorial 
Children’s Hospital in the last ten years (2004-July 2015). The aetiology, presenting clinical features, 
and the association between these clinical features and patient and renal function outcomes were 
characterised. It is hoped that this information will be useful in shedding some light on these questions 
as well as help to provide clues for the direction of further research into crescentic glomerulonephritis 
in children. 
 
 
1.7 Study Question 
What are the incidence, clinical presentation, aetiology and outcome of crescentic glomerulonephritis 
in children presenting to the Red Cross Children’s Hospital in Cape Town over the period 2004 and 
July 2015? 
 
1.8 Objectives  
Main objective 
To determine the incidence, aetiology, clinical features and outcome of crescentic glomerulonephritis 
in children presenting to the Red Cross War Memorial Children’s hospital for renal biopsy. 
Specific objectives 
1. To determine the incidence of crescentic glomerulonephritis in biopsies done over the last 10 
years (2004-July 2015). 
2. To document the various aetiological conditions presenting as crescentic glomerulonephritis. 
3. To establish the renal and patient outcomes for children treated for crescentic 
glomerulonephritis in the last ten years. 
4. To determine the correlation between various patient clinical features and the outcome.  
 
18 
 
1.9 Overview of the Dissertation 
This monograph is arranged into 6 chapters. The first chapter seeks to give a backdrop to the study 
briefly highlighting the knowledge gaps and sets out the aims of the study. In the second chapter we 
present the results of a search of the literature relevant to the stated aims of the study. Chapter three 
presents the study methods and materials while the results are outlined in the fourth chapter. In chapter 
five we discuss the results in light of current literature and then in chapter six we conclude and provide 
recommendations. We used the Vancouver style of referencing and all the references are also presented 
in chapter six. Finally selected documents are presented in the appendices. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.0 Introduction 
Crescentic glomerulonephritis is a medical emergency characterized by severe deterioration in renal 
function over a relatively short period of time that can quickly lead to irreversible kidney injury if not 
appropriately treated early in its course(8). The aetiology is quite varied ranging from primary and 
secondary kidney diseases, genetic conditions, drugs, infections, malignancy and autoimmune 
conditions (1, 12, 15-17). Though the outcome has been reported to be quite poor in many studies, what 
is clear is that early recognition and treatment regardless of the cause seems to improve this outcome. 
Most of this information on crescentic glomerulonephritis is extrapolated from adult series with a 
paucity of large published paediatric series in general and to our knowledge a paucity of published 
paediatric reports from Africa (13, 14, 18). 
In this review we searched the literature for information with an attempt to: 
1. Describe diagnostic criteria for crescentic glomerulonephritis  
2. Describe current theories on the pathophysiology of crescentic glomerulonephritis 
3. Describe what is known  about the Epidemiology of crescentic glomerulonephritis in children 
4. Describe the current treatments  
5. Report on known outcomes of crescentic glomerulonephritis in children and factors that 
influence this outcome as described in the literature. 
Databases were searched using the search terms “Rapidly Progressive Glomerulonephritis” , “ severe 
post-infectious glomerulonephritis” , “ANCA-associated glomerulonephritis”, “Good Pastures disease” 
, “anti- glomerular basement disease” , “ Pauci-immune glomerulonephritis” ,    “ crescentic 
glomerulonephritis” , “children” , “paediatric” , “outcome” , “aetiology”, “treatment”, “Therapy” , 
“Africa” , “developing countries/low resource setting” ,in various combinations. Only articles in 
English were included. 
After the internet search, interesting articles were archived and later a manual search of some of their 
references lists was also carried out to try and locate more information. In addition reference nephrology 
text books were read and their references lists searched in a bid to locate more articles. 
 
2.1 Definition 
Crescentic Glomerulonephritis is a pathological diagnosis marked on histology by the presence of 
crescent shaped lesions in the glomeruli which consist of multiple layers of cells that partially or 
completely fill the urinary space (19). These crescents form as a result of proliferation of parietal and 
visceral epithelial cells and by migration of monocytes and macrophages into the urinary space, the so 
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called extra-capillary proliferation. By definition the presence of fifty percent or more of glomeruli 
exhibiting this lesion is necessary to make the diagnosis(2). The weakness in such a diagnostic criteria 
is that it depends on the renal biopsy sample being adequate so as to allow the inclusion of enough 
glomeruli for examination. But even when the specimen is considered adequate, biopsy may miss more 
extensive focal crescents particularly  in the early stage of  disease (20).This may perhaps be why a few 
studies are reported to have used an arbitrary percentage of glomeruli involved with crescents to make 
the diagnosis (19) (21, 22). 
The clinical correlate is known as rapidly progressive glomerulonephritis (RPGN) and is characterised 
by a decline in renal function over days, weeks or months. It should be remembered however that CGN 
can have an insidious course and cases with only mild derangement of renal function have been 
described (23-25). Other entities such as HUS and proliferative glomerulonephritis without crescents 
can also present with a rapidly progressive course and so form an important differential diagnosis. 
 
2.2 Classification 
The most widely accepted classification of crescentic glomerulonephritis was proposed by Couser in 
1988 (26). In this scheme there are three broad classes of Crescentic Glomerulonephritis. Patients are 
assigned to a sub-type based on renal biopsy immunofluorescence findings as well as on the presence 
of various serological markers. These classes are meant to reflect the possible mechanisms of the 
glomerular injury. These various mechanisms eventually lead to a final common inflammatory cascade 
which then results in the extra-capillary proliferation in Bowman’s space. These groups are: 
a) Anti -Glomerular Basement Membrane Crescentic Glomerulonephritis(Anti-GBM)(Type I)  
 
This entity is uncommon in both the paediatric age group and adults(1). It is caused by the 
presence of auto antibodies directed against a component of the alpha 3 chain of type IV 
collagen that is referred to as Goodpasture antigen. It is a normally a hidden conformational 
epitopes(27). A post- transplant form of the disease occurs in some patients with Alports 
syndrome but the target of the GBM alloantibodies are conformational epitopes in the NC1 
domain of alpha 5 collagen only(27). Anti-GBM nephritis can either occur as a renal-limited 
disease or as a pulmonary –renal vasculitic syndrome (Good pastures syndrome). On histology 
the distinguishing features of this sub-type of crescentic glomerulonephritis is the presence of 
linear sub epithelial deposits of Ig G or rarely IgA on immunofluorescence. The diagnosis is 
confirmed by detection of GBM allo-antibodies on serology. It has been observed however that 
some patients with GBM nephritis will either have undetectable anti-GBM antibodies or that 
they express both anti-GBM allo-antibodies and anti-neutrophil cytoplasmic antibodies 
(ANCA) (1). This is more likely to occur in the renal limited form of the disease. 
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b) Immune mediated Crescentic Glomerulonephritis (Type II) 
This form of CGN accounts for a large proportion of crescentic glomerulonephritis in the 
paediatric age group(1) . It is marked on immunofluorescence by granular deposits of immune 
complexes in the sub-endothelium of the capillary wall and also in the mesangium. There are 
various causes of this histological pattern ranging from post infectious conditions such as post-
streptococcal glomerulonephritis, systemic conditions and primary glomerulonephritides. (26, 
28, 29) 
 
c) Pauci- immune crescentic glomerulonephritis(Type III) 
In the Pauci -Immune Crescentic Glomerulonephritis sub-type, the crescents are often 
circumferential and there are minimal or no immune deposits demonstrated on 
immunofluorescence(1).There are also features of small vessel vasculitis with focal or diffuse 
necrosis(30). Most patients with Pauci- immune glomerulonephritis have a small vessel 
vasculitis such as microscopic polyangiitis or granulomatosis with polyangiitis (Wegener’s). 
Occasionally though the vasculitis may be renal limited(31) . Pauci immune glomerulonephritis 
is more common in Caucasians and adults and shows no sex predilection(1, 32). 
 
2.3 Pathophysiology 
 
2.3.1 A final common pathway-mechanisms 
 It is postulated that the primary event that leads to crescentic glomerulonephritis is an alteration in the 
integrity of the capillary endothelial wall and the basement membrane which results in increased 
permeability. This allows both soluble and cellular pro-inflammatory elements to move into the urinary 
space where they become activated with resultant production of cytokines such as IL1 and TNF alpha. 
The release of chemokines results in the recruitment of further pro-inflammatory mediators such as 
macrophages and lymphocytes as well as stimulation of the proliferation of both visceral and parietal 
epithelial cells with subsequent formation of the characteristic crescent shaped lesions in the 
glomerulus. There is some evidence that renal progenitor cells may be involved in the formation of this 
hyperplastic lesion(33). The presence of these glomerular crescents is not specific to a particular disease 
but rather their presence is simply an indicator of the severity of the glomerular injury. 
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With time the inflammatory infiltrate may either resolve with resultant restoration of normal glomerular 
architecture or may progress to formation of fibrinous tissue which may lead to irreversible loss of renal 
function(10) 
 
Fig. 4 The final common pathway in the pathogenesis of crescentic glomerulonephritis 
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2.3.2 Mechanism of glomerular injury in Type II /immune mediated crescentic glomerulonephritis 
The causes of Type II crescentic glomerulonephritis are heterogeneous. What is common to all of them 
is that the mechanism of glomerular injury involves the localization of immune complexes in the 
capillary wall or mesangium. These immune complexes may be formed in-situ or by deposition of 
already formed circulating immune complexes. Once deposited the immune complexes cause activation 
of the inflammatory cascade via the intermediacy of various factors such as the soluble mediators of 
coagulation, blood cells (neutrophils, macrophages, platelets) and cytokines. If the resulting 
inflammatory damage breaches the capillary wall then an extra-capillary pattern of cellular proliferation 
results which then leads to formation of crescents(1, 10). 
There are various theories over what the determinants of the severity of the glomerular injury might be 
in the various causes of immune complex crescentic glomerulonephritis (2, 34, 35). For example it has 
been reported that up to 25% of patients with immune complex crescentic glomerulonephritis have 
circulating ANCA as opposed to only less than 5% of patients with non-crescentic immune complex 
glomerulonephritis. This has led some investigators to postulate that ANCAs may predispose to more 
severe forms of glomerular injury in patients with immune complex mediated glomerulonephritis(2). 
 
2.3.3 Mechanisms of glomerular injury in Pauci- immune crescentic glomerulonephritis 
The exact mechanism of glomerular injury in Pauci-immune glomerulonephritis has not been 
completely elucidated but it is postulated that in most patients the Anti-neutrophil Cytoplasmic 
Antibodies (ANCA) plays a key role since they are detected in the serum of up to 80% of patients (1, 
31, 35, 36) 
Anti-neutrophil cytoplasmic antibodies (ANCAs) are autoantibodies, mainly of the IgG class that are 
directed against antigens in the granules of neutrophils and the lysosomes of monocytes. They mainly 
target the enzymes myeloperoxidase (MPO) and proteinase 3(PR3)(31).The pattern of distribution of 
antibodies on immunofluorescence is used to sub-classify ANCAs into two main groups. 
 Cytoplasmic ANCA(c-ANCA)-these have a cytoplasmic staining pattern resulting 
from binding of ANCAs to antigen targets throughout the neutrophil cytoplasm.  
 
 Peri-nuclear ANCA (p-ANCA)-these have a staining pattern around the region of the 
nucleus. Since the nucleus is negatively charged because of the Deoxyribonucleic acid 
24 
 
content while most of the antigens targeted by ANCAs are positively charged at neutral 
pH, during ethanol fixation, these positive antigens will migrate and surround the 
negatively charged nucleus. Antibody staining therefore results in florescence of the 
region around the nucleus giving rise to the observed pattern. 
About 90 % of c-ANCA are targeted against PR3 while 70 % of p-ANCA are reactive against MPO. 
What causes the initial production of ANCA in the first place remains a mystery but numerous 
hypotheses have implicated various factors such as exposure to silica, Staphylococcus aureus, genetic 
predisposition, parvo B19 and anti-thyroid drugs (36, 37). 
Though the exact mechanism of the initiating factors for ANCA formation and indeed for the resulting 
glomerular injury remain unknown, it is postulated that via stimulation by either cytokines or altered 
antigen gene expression, the antigen targets of ANCA which are normally inaccessible in the neutrophil 
cytoplasm become externalised and expressed at the cell surface. In the presence of circulating ANCA, 
there is an interaction between the autoantibody and the externalised antigens which leads to the 
activation of the neutrophil. Additionally there is evidence that the MPO and the PR3 antigens may be 
internalized via an active transport mechanism by endothelial cells. This results in a myriad things 
including the production of cytokines like interleukin 18 which is a pro-inflammatory factor.   
The activation of neutrophils causes them to go through the respiratory burst which subsequently leads 
to the release of both primary and secondary granules and this ultimately causes the release of toxic 
oxygen radicals and other lytic substances at the site of the vessel wall thus producing a necrotizing 
inflammatory injury. Evidence against this hypothesis include the fact that up to 20 % of patients with 
Pauci-immune glomerulonephritis are ANCA negative and that often ANCA titres do not correlate with 
disease activity(22, 31). In addition ANCA occur in perfectly normal people who have no evidence of 
disease. 
 
2.3.4 Mechanisms of glomerular injury anti glomerular basement antibody crescentic 
glomerulonephritis 
It is postulated that by an as yet unknown mechanism, the usually hidden conformational epitopes of 
the type IV collagen (EA and EB) become exposed and that there is an induction of B cells to produce 
circulating anti-glomerular basement membrane autoantibodies (27, 38) 
Some of the factors that are postulated to cause the unveiling of these cryptic epitopes include exposure 
to tobacco smoke, endogenous oxidants and hydrocarbons (39) (40) (41). The significance of these 
factors in paediatric patients has not been demonstrated though. 
It is believed that these anti-GBM autoantibodies bind to the exposed epitopes and that this then results 
in the activation of neutrophils with the subsequent recruitment of other inflammatory factors. This 
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leads to the well described inflammatory cascade that leads to the glomerular injury that eventually 
results in crescent formation. It is important to remember though that despite being largely believed to 
be  an antibody mediated glomerulonephritis, there has been some evidence for the role of T-
lymphocytes in the initiation of the inflammatory cascade  that results in anti-GBM disease((42)  (43) 
 
2.4 Epidemiology 
 The estimated incidence of crescentic glomerulonephritis is about 7 cases per million population per 
year and one study noted that it accounted for only 5 % of unselected renal biopsies in children (7, 44) 
.The importance of each of the immune-pathologic sub groups varies depending on various factors. 
Generally  anti- GBM crescentic glomerulonephritis is rare across all age groups but is more prevalent 
in adults(1) The Pauci-immune subtype tends to be more common in older individuals while immune-
complex mediated crescentic glomerulonephritis is more likely to be diagnosed in the paediatric age 
group(44-46).  
Table 1 illustrates findings from the North Carolina biopsy series. Pauci-immune glomerulonephritis 
was the most likely cause of RPGN in adults whereas in children the immune- mediated variety is more 
prevalent. In more recent times many paediatric series have reported an increased proportion of 
crescentic glomerulonephritis being due to the Pauci-immune subtype particularly in the industrialised 
countries for example Japan (15). This trend was however not described in a ten year retrospective study 
conducted in Wessex(47)  
 
Table 2. Effect of age on sub-type of CGN-adapted from the North Carolina Series(1) 
IMMUNOPATHOLOGIC 
CATEGORY(47) 
    
ALL AGES (N=632) 1-20 YRS   (N=73) 21-60 YR 
(N=303) 
>60 YR 
(N=256) 
 
Anti-glomerular basement CGN 
  92 (15%)  9 (12%)  44 (15%)  39 (15%) 
 
Immune complex CGN 
 
 154 ( 24% )   33 (45% )   106 ( 35% )    15 (6% ) 
 
Pauci-immune CGN 
 
377 ( 60 % )  31 ( 42% )  145 ( 48% )  201 (79 % ) 
 
0ther  
 
  9 ( 1 % )    0   8 ( 3 % )   0 
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The data from studies conducted in different regions of the world show a striking difference in the 
aetiologies of immune-complex mediated crescentic glomerulonephritis (table 2). Generally speaking 
studies from less developed countries continue to show the relative importance of post-infectious 
glomerulonephritis whereas studies from more industrialized countries tend to show that this subgroup 
of causes has become less important (12-14, 25, 44, 46). In addition to this, an evaluation of cases from 
the more affluent countries has shown that with increased industrialisation and improved standards of 
living the trends over time have seen the proportion of post infectious glomerulonephritis dropping off 
(48-50). 
 
Table 3. Aetiology of immune-complex CGN from various series 
 Jardim(51)UK 
 
 
 
(N=30) 
Srivastava,et,al(25) 
 New Delhi  
 
 
(N=43) 
Dewan et al(44) 
 
 
 
(N=22) 
Parag 
Natal 
al(14) 
 
(N=27) 
Zent et al, 
cape town 
(12) 
 
(N=73) 
Sinha et 
al(45) 
India 
 
(N=36) 
Post infectious GN 6.6% 25.5% 31.8 29.2% 28.7% 8.3% 
Systemic Lupus 
Erythematosus 
3.3% 2.3% 9.1% 3.7% 20.5% 11% 
HSP, IgA nephropathy 30% 6.9% 13.6% - - 11% 
Membranoproliferative 
GN 
23.3%       - 13.6% 11.1% - 5.5% 
0thers   18.2 26% -  
Others causes of CGN 
In the series 
34% 65% 15% 32% - - 
 
 
Table 2 above shows the various aetiologies of immune-complex crescentic glomerulonephritis as 
reported in various series that included children from various parts of the world. The study by Zent et 
al was conducted at Groote Schuur Hospital, in Cape Town. Although the subjects were adults we 
included this series because it was done in a population very similar to our study population in many 
other respects. What was striking about the results from this study was the high prevalence of crescentic 
lupus nephritis as well as post-infectious crescentic glomerulonephritis particularly since the subjects 
were adults. (14, 44). 
Ethnicity is known to influence the epidemiology of crescentic glomerulonephritis. For example 
numerous studies continue to report a higher prevalence of post-infectious crescentic 
glomerulonephritis among black patients and indigenous racial groups on other continents (12-14, 52). 
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This is probably a reflection of the disadvantaged socio-economic circumstances of these groups of 
people (48). 
Pauci- immune crescentic glomerulonephritis on the other hand is more common in Caucasians and has 
no sex predilection(1). A study conducted exclusively in a paediatric cohort in Japan however showed 
a higher prevalence in girls(53). In a nationwide survey also in Japan there was a noted higher 
prevalence (64%) of this subtype as a cause of rapidly progressive glomerulonephritis(15).In a study 
examining ANCA associated glomerulonephritis in African –American, the outcome was noted to be 
similar to that in Caucasians. It is worth noting that many of these studies were done in studies that 
included adults and thus the same may not necessarily be true in the paediatric population. 
 
2.5. Treatment  
The treatment of crescentic glomerulonephritis can be divided into supportive and specific(3). 
Supportive management includes correction of fluid overload, correction of electrolyte imbalances, 
treatment of infections and any other symptoms associated with renal dysfunction. Specific treatment 
on the other hand is directed at mitigating against the immune mechanisms causing renal dysfunction. 
Most of the evidence concerning the efficacy of various therapeutic strategies directed at childhood 
crescentic glomerulonephritis is extrapolated from case series and adult data (31). We shall briefly 
review two of the treatment guidelines for crescentic glomerulonephritis from two international kidney 
organisations: The kidney disease improving global outcomes (KDIGO) and the National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI). 
The kidney disease improving global outcomes (KDIGO) group is the major organisation that 
formulates evidence based clinical practice guidelines for kidney diseases(54). These guidelines are 
meant to be applicable all over the world. National kidney organisations such as NKF KDOQI, will 
often review these guidelines in order to make them more applicable to their local conditions(54). 
 
2.5.1. Treatment ANCA associated vasculitis 
Table 5 is a summary of the KDIGO recommended treatment guidelines in Pauci-immune crescentic 
glomerulonephritis in various patient populations along with some of the evidence supporting these 
recommendations(31). The recommendation that all patients with necrotizing and crescentic 
glomerulonephritis be treated with corticosteroids and cyclophosphamide was based on the fact that the 
outcome without therapy is universally poor and also due to the fact that many studies clearly show an 
improvement in renal outcomes with treatment. They recommend that all patients with extra-renal 
manifestations of disease receive immunosuppression regardless of the level of renal dysfunction. 
Prudence is advised when it comes to patients already requiring dialysis but with no extra renal 
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manifestations of disease. The guideline cites evidence which shows that close to half of the patients 
with an estimated GFR below 10 ml/min/1.73 m2 at initial presentation, who received 
immunosuppression were noted to have regained function a year later. However for patients showing 
obsolescence of all glomeruli and severe tubular atrophy the benefit of treatment is said to be doubtful 
(55, 56). Caution is also advised in the case of patients who remain dialysis dependant after 3 months 
of cyclophosphamide. In this case the guidelines state that the cyclophosphamide be stopped. This is 
because of evidence that shows that the majority of patients who enter remission do so within the first 
three months of treatment with cyclophosphamide.  
 
Table 4:KDIGO recommended treatment regimens for induction of remission in ANCA 
vasculitis with glomerulonephritis-adapted from(31) 
Agent Route Indication 
Cyclophosphamide  I.V or P.O for 3-6 months 
 
 
All patients- unless 
contraindicated 
Corticosteroids  for 3 days I.V 
 
 
 
All patients 
Corticosteroids  P.O 
 
 
All patients 
Rituximab I.V weekly x4 Alternative initial treatment in 
patients without severe disease 
or in whom cyclophosphamide 
is contraindicated 
Plasmapheresis  60 ml/kg volume replacement -patients requiring dialysis or 
with rapidly increasing serum 
creatinine 
-patients with overlap 
syndrome of ANCA vasculitis 
and anti-GBM GN 
-patients with diffuse 
pulmonary haemorrhage 
- 
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The decision as to whether the cyclophosphamide should be given as  oral or intravenous pulses depends 
upon the treating physicians/patient/family assessment of potential for compliance, cost implications, 
cumulative dose of cyclophosphamide and risk of infection(31). Otherwise the oral and intravenous 
routes are associated with similar rates of remission and relapse(57). 
In addition the guidelines provide evidence that indicates that Rituximab is just as efficacious as 
cyclophosphamide but questions the wider applicability of its use globally due to the cost of the 
drug(58).  
Furthermore, plasmapheresis is advocated for severe necrotizing crescentic glomerulonephritis. 
Evidence is quoted from a multicentre trial which showed improved renal outcomes in patients 
presenting with advanced kidney dysfunction which was defined as a serum creatinine greater than 500 
micromoles/litre(59). Evidence for use of plasmapheresis in patients with serum creatinine less than 
500 micromoles/litre was said not to be as strong(60).No equivalent threshold is provided for the 
paediatric population. Since the range of body mass in paediatric patients is widely ranging perhaps use 
of a threshold based on glomerular filtration rate would be more appropriate for this age group. The 
guideline also brings attention to the fact that most evidence for the effectiveness of plasmapheresis in 
the setting of severe diffuse pulmonary haemorrhage is based on retrospective case series but 
recommends its use due to the associated reduction in mortality in these series (61-63). 
In commenting on the fore-going recommendations the kidney disease outcome quality initiative 
(KDOQI) group raises a few questions(54). While concurring with KDIGO guidance on the use of 
corticosteroids and cyclophosphamide in the initial management, they point out the fact that the 
evidence on the dose of intravenous cyclophosphamide is scant and that it is based on lupus nephritis 
treatment protocols. In addition they contend that rituximab is as efficacious as cyclophosphamide even 
for severe disease as illustrated in patients in the RITUXVAS (rituximab versus cyclophosphamide in 
ANCA-associated vasculitis) and RAVE (rituximab in ANCA-associated vasculitis) trials who all had 
newly diagnosed severe disease(58, 64). This comment does not apply to patients on mechanical 
ventilation or those with very severe renal disease. They do concede though that there is not as much 
long term experience with rituximab as compared to cyclophosphamide.  
The KDOQI commentary endorses the use of methotrexate and corticosteroids for induction of 
remission in non-severe extra renal disease but contends that the evidence for the use of MMF for 
induction is not strong enough. Furthermore they failed to find evidence for the use of azathioprine for 
induction therapy. 
With regards to the use of plasmapheresis in Pauci-immune crescentic glomerulonephritis, KDOQI 
casts some doubt on the presence of strong evidence on the long term benefit based on new data from 
the MEPEX (methyl prednisolone or plasma exchange for renal vasculitis) trial. In addition they raise 
concerns about the need for clinicians to be aware of the risk of plasmapheresis removing rituximab 
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and therefore the need for appropriate dose timing. Other risks associated with plasmapheresis such as 
infection, hemodynamic shifts are also highlighted. In the context of pulmonary haemorrhage though 
the evidence is not strong since it was acquired from retrospective case series, the impact i.e. reduced 
mortality is recognised as high. 
Both work groups advocated for the use of maintenance therapy after induction of remission for the 
duration of at least 18 months. Patients with renal limited disease and are still on dialysis 3 months after 
initiation of induction therapy should have immunosuppression withdrawn due to the higher risk of 
infection compared to the benefit of therapy. Choices of drugs include azathioprine, MMF and 
methotrexate. Both contend that there is no actual trial evidence for the use of maintenance therapy after 
rituximab though both groups advice for maintenance in this context due to evidence showing presence 
of relapse five months to years after use of rituximab. 
 
2.5.2. Treatment of anti-GBM crescentic glomerulonephritis 
The KDIGO 2012 glomerulonephritis clinical guidelines recognise that the anti -GBM antibodies in 
this condition are pathogenic and support the use of a treatment strategy that removes these antibodies, 
reduces further elaboration of antibodies by immune cells as well as mitigates the inflammatory damage 
that may be on going in the kidneys and other tissues(31).  
In brief the guidance for induction of remission is that all patients should receive corticosteroids, 
cyclophosphamide as well as 14 days of plasmapheresis or until anti-GBM antibodies become 
undetectable. The exception is in patients with renal disease in which there is involvement of 80-100% 
of glomeruli by crescents. All patients with major pulmonary haemorrhage are meant to receive 
plasmapheresis regardless of the percentage of glomeruli involved in crescent formation. They do point 
out though the fact that the evidence for plasmapheresis is not very robust(31). 
In commenting on the above guidance KDOQI essentially concurs with the exception of reiterating that 
there may be a case for trial of cyclophosphamide in some selected patients even in the presence of 80-
100% of glomeruli that are involved with crescents(54) 
With regards to maintenance therapy both groups advise against the use of this in the context of anti-
glomerular basement disease. This is because of the fleeting nature of the anti-glomerular basement 
membrane antibodies. KDOQI, however offer the suggestion that azathioprine can possibly be used as 
maintenance therapy in the very rare event that a relapse doe as occur. Both guidelines counsel that 
transplantation be deferred until antibodies become undetectable as they are known to be pathogenic. 
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2.5.3. Treatment immune-complex crescentic glomerulonephritis 
The specific therapy directed at immune- complex crescentic glomerulonephritis depends on what the 
underlying diagnosis is(3). The treatment for IgA nephropathy, Henoch Schonlein purpura or systemic 
lupus erythematosus associated crescentic glomerulonephritis is based on the respective protocols for 
these particular disease conditions. The situation is rather unclear for post infectious severe 
glomerulonephritis and idiopathic immune-complex crescentic glomerulonephritis but generally 
children are given an initial course of pulse corticosteroids followed by a tapering of prednisone over a 
three month period by most nephrologist with only a few preferring to add on cyclophosphamide for a 
select few patients. 
 
2.6 Outcome  
The long term renal outcome of childhood crescentic glomerulonephritis is described as poor in at 
least half of the patients in many of the case series (3, 44-46, 65). Table 4 below shows the renal 
outcome as reported in a few series from across the world. 
 
Table 5: Renal outcome of crescentic glomerulonephritis from various series 
 Thailand (66) United 
kingdom(51) 
Dilima(13) New Delhi, 
India(44) 
Natal, 
South 
Africa(14) 
ESRD 
 
50% 50% 75% 45% 45% 
Death  
 
- 10% - - 16.6 % 
 
 
Some of the determinants that have been descried as being associated with adverse renal outcome 
include the percentage of fibro-cellular crescents, the extent of global sclerosis, the time to treatment, 
the need for dialysis at presentation, the presence of oliguria as well as the presence of hypertension 
and nephrotic range proteinuria during the follow up period (25, 44, 46, 65, 66). One study noted that 
the prognosis of renal survival after post infectious rapidly progressive glomerulonephritis was 
particularly poor(67) 
Thus, though crescentic glomerulonephritis is uncommon in the paediatric age group it is an important 
and preventable cause of end stage renal disease. The prevalence of the three immune-pathologic sub 
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types is influenced by factors such as age, ethnicity and geography. And as with many other disease 
conditions there is very little data describing crescentic glomerulonephritis with regards aetiology and 
outcome in children in an African setting. This study was an attempt to help bridge that knowledge gap 
and it is hoped that the data collected will both help improve patient care as well as act to guide future 
research efforts. 
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CHAPTER 3: MATERIALS AND METHODS 
 
This study was conducted in an attempt to determine the aetiology, clinical features and 
outcomes of crescentic glomerulonephritis in a quaternary care hospital in Cape Town. This 
chapter outlines the study design, the data collection tools, the ethical considerations and the 
statistical methods used to analyse the collected data. 
 
          3.1 The study site                      
 (68) 
The study site is located in South Africa’s fourth largest province, the Western Cape. The 
province has an estimated population of 5,223,908 with people of mixed race accounting for 
50.2%, Black people accounting for 30.1%, White people accounting for 18.4% and 
Indian/Asian accounting for 1.3%. Two million of the population are aged below 20 years (68). 
The study site was the Red Cross War Memorial Children’s Hospital which was established in 
1956 and is the only paediatric hospital in the sub-region. The hospital provides quaternary 
level care in all major specialties, to children referred from across the breadth of South Africa 
and even beyond the country’s borders. 
Children with renal problems are cared for in a consultant lead 12 bed nephrology unit which 
has the capacity to provide all forms of renal replacement therapy and has ready access to 
critical care, laboratory, radiology and pathology support services.  
 
3.2 Study design and population 
The study was a retrospective folder review and the population consisted of native kidney 
biopsies of children below 18 years that had been performed at the Red Cross War Memorial 
Children’s Hospital between 2004 and July 2015. 
 
3.3 Selection of Subjects 
The results of renal biopsies conducted in children at the Red Cross War Memorial Children’s 
Hospital between 2004 and July 2015 were reviewed and all those biopsy results meeting the 
case definition were included in the study. 
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    3.4 Case definition 
In this study a child was considered to have crescentic glomerulonephritis if they had 
crescents in at least 50% of glomeruli as determined in their original biopsy report. 
 
3.5 Inclusion criteria 
 
To be included in the study the following criteria had to be met: 
 Child aged 18 years and below 
 Child meeting the criteria for case definition 
 Available case records( notes and/or laboratory reports and/or treatment charts) 
    3.6 Clinical Assessment 
The record of all renal biopsies conducted in the relevant study period were reviewed. Once the 
children who were diagnosed as having crescentic glomerulonephritis were identified, their 
clinical records were assessed. The demographic data, clinical features, laboratory and 
pathological characteristics were then recorded in the data collection tool (Appendix A). 
 
 
3.7 Data Management and Analysis 
 
3.7.1. Dependent (outcome) variables:  
  The study dependant variables included the following:  
 biopsy results 
 aetiology 
 outcome of renal function 
 
3.7.2 Independent (predictor) variables 
                 The study independent variables included the following:  
 Age 
 Sex  
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 Ethnicity – as self-identified by patient 
 Region of origin i.e. province 
 Duration of illness before diagnosis i.e. time elapsed between onset of symptoms and 
presentation. 
 Number of rooms in home 
 Estimated monthly family income 
 Season 
 Serologic markers(anti-nuclear antibody (ANA), anti- neutrophil cytoplasmic antibody 
(ANCA), anti-double stranded DNA (dsDNA) and serum complement levels , anti-
streptolysin O titres (ASOT) , Anti DNase B ),RPR. 
 Admission blood pressure- A patient was considered to be hypertensive if their arterial 
blood pressure was greater than the 95 percentile for age, sex and height according to the 
paediatric hypertension percentile charts (69).  
 Biochemical parameters (serum creatinine and estimated glomerular filtration rate 
(eGFR) at diagnosis and at last follow-up, highest creatinine, urine examination, urine 
protein level). The estimated GFR was calculated using the Schwartz formula(70). 
 Human Immune Virus (HIV) serological status 
 Duration of follow-up 
 Therapeutic regime given( the number of doses of methyl-prednisone or 
cyclophosphamide)  
 The clinical outcome (patient death, chronic kidney disease (CKD) stage, renal 
replacement therapy at one year and at last follow up).The Kidney Disease Outcome 
Quality Initiative (K/DOQI) classification of chronic kidney disease was used as shown 
in table 5 below(71). 
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                           Table 6: K/DOQI stages of chronic kidney disease(71) 
Chronic Kidney Disease Stage  Glomerular filtration rate  
(ml/min/1.73m2 ) 
1 >90 
2 60-89 
3 30-59 
4 15-29 
5 < 15 
 
 
 The pathological characteristics of the patient biopsy as reported in the original report 
(total number of glomeruli, proportion of glomeruli with fibro-cellular/cellular/fibrous 
crescents, the degree of interstitial fibrosis and tubular atrophy). 
 
3.7.3 Data management and analysis 
A secondary data base was created in SPSS version 22. The baseline information on the patients 
was obtained from the data collection tool. We analysed the data using SPSS. Simple proportions 
were used to calculate the incidence of crescentic glomerulonephritis in the Red Cross renal biopsy 
series. Simple proportions were also used to analyse categorical data .Continuous variables were 
analysed by calculating means. The association of the categorical variables to renal outcome were 
assessed by using the Fischer’s exact test because in almost all the analyses there were some cells 
that contained less than 5 items due to a small sample size. A p value < 0.05 was considered as 
significant.  
  
3.8 Ethical Considerations 
The study was conducted in compliance with the South African Guideline for Good Clinical 
Practice and the Medical Research Council Ethical guidelines. Approvals to conduct this study were 
obtained from the University of Cape Town Department of Paediatrics and Child Health Research 
Committee, the University of Cape Town Ethics Review Board and the Red Cross Children’s 
Hospital management. 
1. Research procedure and data collection 
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As outlined above. 
 
2. Outputs  
The findings of the study will be presented as part of a thesis to the University of Cape 
Town and may be published in a peer reviewed journal. 
 
3. Anticipated gain in scientific knowledge 
There are only a handful of studies that have been carried out to study crescentic 
glomerulonephritis in Africa to try and characterise the aetiology and outcomes of this 
entity. Thus the results from this study will help to fill this knowledge gap and perhaps give 
clinicians information that may be useful when managing children with crescentic 
glomerulonephritis in this population. 
 
 
4. Description of risks and benefits 
 As this was a retrospective study there were no additional risks to the patients. 
 There was no direct benefits to the patients included in the study. However, the study has 
provided information that may give new insights into the common aetiologies and usual 
outcomes of crescentic glomerulonephritis in children in this population. This knowledge 
may assist clinicians managing future patients who present with crescentic 
glomerulonephritis. 
 
5. Privacy and Confidentiality 
Once patient information had been entered into the study data base only a coded study 
number was used as an identifier. The identifying details were kept in a separate file with 
access restricted to only the investigators.  
 
6. Reimbursement for participation 
 Not applicable as this was a review of patient records. 
 
7. Emergency care and insurance for research-related injuries 
This did not apply as this was a review of patient records  
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CHAPTER 4: RESULTS 
 
4.0 Recruitment of study subjects and incidence of crescentic glomerulonephritis 
Figure 5. is a flow chart that illustrates how the selection of the subjects was conducted. A total of 540 
renal biopsies were performed at the Red Cross children’s hospital between 2004 and June 2015. Of 
these, transplant kidney biopsies and biopsies with insufficient material were excluded from the 
analysis. Thus a total of 470 native kidney biopsy results were assessed. Of these, 24 biopsies showed 
crescentic glomerulonephritis thus accounting for an incidence of 5.1% in this biopsy series. 
Fig 5. Flow chart showing selection of study subjects 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
Total Number of biopsies at RXH 2004-2015 
                                540 
Native Kidney Biopsies 
470 
Not Eligible 
Transplant/inadequate 
biopsy 
70 
 
 
Crescentic Glomerulonephritis 
24 
Other glomerular 
diseases 
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4.1 Demographic and Baseline Characteristics of the subjects 
Table 7. Summarizes the demographic and baseline characteristics of the subjects. The children’s mean 
age was 8.3+/- 3.4 year with an age range of 1 year to 14 years. Most of the children (14, 58.5%) were 
aged 5 to 10 years, while 7(29.2%) were aged greater than 10 years and 3(12.5%) were younger than 
five years old. The predominant sex of the children was male (14, 58.3%) thus giving a male to female 
ratio of 1.4. 
The race of the subjects was defined as the race that the subject had identified themselves as belonging 
to as indicated in their hospital records. This information was unavailable for 17 (62%) of the children. 
The racial distribution of the remaining children was black 6 (25%), Asian 1 (4%) and mixed race 1 
(4%). 
We were unable to determine the living conditions of most of the children from the retrospective 
inspection of the records therefore this was left out of the analysis. Similarly the socio-economic status 
of families was difficult to establish in a meaningful way.  
The Year was divided into four quarters roughly corresponding to the four seasons experienced in the 
Western Cape Province. As illustrated in Fig 6, most of the children (11, 45.8%) presented in the winter, 
followed by those that presented in the spring (7, 29.2%), summer (5, 20.8%) and autumn (1, 4.1%). 
The majority of the subjects (13, 58.3%) had been referred from health facilities within the Western 
Cape Province. Of these children coming from within the Western Cape Province, 10 were referred 
from health centres within the city of Cape Town. In total 10 children came from outside the province. 
Of these 2 were foreign nationals (Namibia, Zimbabwe) while the remaining 8 were referred from the 
Eastern Cape Province. Due to missing record the referral heath facility of one patient was 
undetermined. 
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Table 7: Demographic characteristics of the participants 
Patient 
No.                     
Aetiology Age Sex Month of 
presentation 
place of origin 
1 Post infectious 5 Male July CTC 
2 SLE 10 Female  May  OWCP 
3 Post infectious 3 Female  October  CTC  
4 p-ANCA renal 
limited vasculitis 
11 Female  November  OWCP 
5 HSP 11 Female  September  CTC 
6 p-ANCA 
vasculitis 
5 Female  December  WCP 
7 Post streptococcal 6 Male  May   OWCP 
8 IC-idiopathic 8 Male  January  OWCP 
9 IC-idiopathic 14 Male March  OWCP 
10 IgA nephropathy 12 Male  November  WCP 
11 Post-streptococcal 9 Male  August  OWCP 
12 CGN-unspecified 12 Female  September  WCP 
13 IC-idiopathic  13 Female    September CTC 
14 IC-idiopathic 4 Male  May  OWCP 
15 Mesangiocapillary 
GN 
5 Male  June  CTC 
16 Post-streptococcal 10 Male  November  CTC 
17 Post-streptococcal 6 Male September   CTC 
18 Post-streptococcal 9 Male  May  OWCP 
19 Post-streptococcal 7 Female  June  OWCP 
20 Post-streptococcal 10 Male July  CTC 
21 Post infectious 10 Male  August CTC 
22 Pauci-immune 13 Male  May - 
23 CGN- unspecified 6 Female June   OWCP 
24 Post-streptococcal 12 Female  May  CTC 
 
CTC-Cape Town City, WCP- Western Cape Province, OWCP-Outside Western Cape Province, IC-immune-complex 
CGN-crescentic glomerulonephritis 
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Fig.6 – Seasonal distribution of the crescentic glomerulonephritis cases 
 
 
 
4.2 Clinical and Laboratory Characteristics of the subjects 
Table 8. Shows the initial anthropometric measurements of the subjects. We were only able to find 
records of the initial anthropometric measurements for 20 out of all the 24 children who presented with 
crescentic glomerulonephritis during the study period. World Health Organisation (WHO) growth 
charts were used to evaluate the children’s anthropometric measurements(72). The following categories 
are recognised based on these charts: 
 Overweight: greater than +1 standard deviation 
 Obesity: greater than + 2 standard deviations 
 Thinness: less than -2 standard deviations 
 Severe thinness: less than -3 standard deviations 
None of the children was found to be stunted at presentation. Only 2 children were obese while only 
one child had severe thinness based on body mass index (BMI).  
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Table 8: Anthropometric characteristics of the study subjects 
Patient 
No.                     
Age Sex Weight 
[Kg] 
Height(z-score) 
 
BMI   (z-score) 
1 5 Male 22.9 1.2   ( +1) 17          (< +1) 
2 10 Female  36 1.3   (< -1) 20          (< +2) 
3 3 Female  12.9 0.93 15        (<median) 
4 11 Female  41.1  1.4  (<med) 21         (< +2) 
5 11 Female  34.4 1.5  (<+1) 16        (<median) 
6 5 Female  24.7 1.0   (-1) 23          (> +3) 
7 6 Male  23.4 1.2   (+1) 17          ( < +2) 
8 8 Male  24.4 1.3    (+1) 15         (median) 
9 14 Male 50 1.5     (-2) 23          (< +2) 
10 12 Male  28.4 1.5    (<med) 14           (< -3) 
11 9 Male  25 1.2    (<-1) 17           (< +2) 
12 12 Female  40 1.5   (med) 18          (median) 
13 13 Female    47.3 1.5   (<med) 20           (< +1) 
14 4 Male  21.9 1.0 22            (> +3) 
15 5 Male  10 1.0  (-2) 10             (< -3) 
16 10 Male  45.5 1.4  (<+1) 23             (< +3) 
17 6 Male 18.6 1.2(<+1) 13              (-1) 
18 9 Male  32.6 1.4(<+1) 18              (< +2) 
19 7 Female  28.1 1.3(<+1) 17               (+1) 
20 10 Male 32.8 1.3(<med) 19              (< +2) 
21 10 Male  - - - 
22 13 Male  - - -  
23 6 Female - - - 
24 12 Female  - - - 
 
Table 9.  Tabulates selected clinical and laboratory characteristics of the study subjects.  The mean 
number of days that symptoms had been present prior to presentation to Red Cross Hospital was 21.4 
+/- 40.6 days. The range for the time it took for patients to present was 1 day to 180 days. The time that 
lapsed between onset of symptoms and presentation to Red Cross Hospital was categorised into three 
blocks: a) symptoms present for less than a week prior to presentation b) symptoms present between 
one and two weeks prior to presentation and c) symptoms present for more than two weeks prior to 
presentation to Red Cross Hospital. Symptoms had been present for less than a week in 6(30%), present 
between one to two weeks in 6(30%) and for greater than two weeks in another 6(30%). Records were 
only available for 18 children. 
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Table 9: Patient clinical characteristics at initial presentation 
Patient 
[N=18]                     
Time 
between
symptom 
onset and 
presentation 
to RXCH  
Admission 
BP 
Macroscopic 
Haematuria 
Proteinuria 
g/mmol 
Hb 
g/dl 
 Initial 
Creatinine 
micromoles/l 
eGFR 
ml/min/1.73
m2 
1 3 130/100 Yes  - 10.6 534 8.7 
2 28  118/60 No  1.1 5.4 1361 3.9 
3 7 130/99 No  4.35 4.2 200 18.6 
4 10 195/135 No - 7.1 1381 4.0 
5 180 135/60 Yes  1.0 10.6 95 62 
6 28  115/80 No 0.73 7.3 273 15.2 
7 2 140/75  Yes  0.20 5.9 1195 4.0 
8 - -  Yes  0.45 6.6 1108 4.6 
9 14 160/100  Yes  0.56 10 218 27.2 
10 21 133/73  Yes  0.69 11.1 155 37.4 
11 7 126/89 Yes  1.36 8.1 1174 4.2 
12 14 130/50 No 0.30 4.0 762 8.0 
13 28 115/90 Yes  2.89 - 262 23.4 
14 3 150/100 Yes 1.90 7.9 383 10.7 
16 7 190/123 No  - 8.6 306 18.0 
17 21 140/95 Yes - 10 80 58.6 
19 6 119/90 No - 9.7 207 9.9 
20 1 150/90  No  - 12  28.9 
 
RXCH- Red Cross Memorial Childrens Hospital 
 
The records of 19 children were available for assessment of blood pressure at presentation. Seventeen 
(90%) of the children were hypertensive while 2(10%) were not. Macroscopic haematuria was present 
in 10 (55.5%) of these children. Records on macroscopic haematuria were only available for 18 of the 
children 
Records for the evaluation of proteinuria were available in 14 of the subjects. The mean urine protein 
to creatinine ratio was 1.1g/mmol +/- 1.2 g/mmol with a range of 0.1-4.3 g/mmol. Nephrotic range 
proteinuria [>0.2 g/mmol] was present in 11(80%) of the children. 
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Figure 7 below illustrates the frequency with which various clinical features occurred in the study 
subjects. Full records were only available for 18 of the children. Of note is the high prevalence of 
oedema (17, 94%), anaemia (15, 88%) and hyperphosphatemia (9, 50%). In contrast only 1 patient had 
haemoptysis, and only 5(30%) had hyponatraemia. 
 
Figure 7. Frequency of various patient clinical characteristics  
 
 
 
Table 10 below shows results of the initial renal function in the study subjects. A record was only 
available for 18 of the subjects. The mean urea was 33.3 mmol/l +/- 17.4 mmol/l while the mean serum 
creatinine at presentation was 566.8 +/- 465 micromoles/l. The range for serum creatinine was 80-1381 
micromoles /l. The mean estimated GFR at initial presentation was 18 ml/min/1.73m2 +/- 17.9 
ml/min/1.73m2 with a range of 3.9 to 62 ml/min/1.73 m2 .Half (9) of the children had an initial estimated 
GFR below 10ml/min/1.73 m2 . 
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Table 10: Summary of patient renal function at initial presentation 
Parameter  
N=18 
Minimum value Maximum  
value 
Mean  
Value 
Standard  
Deviation 
Serum 
Urea mmol/L 
9 65 33.3 17.4 
Serum  
Creatinine 
micromole/l 
80 1381 566.8 465 
Estimated 
GFR 
ml/min/1.73m2 
3.9 62 18 17.9 
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Table 11: Result of various serological immune markers in the subjects 
Patient 
No.                     
Aetiology C3 C4 ASOT Anti-
DNase B 
ANCA Anti-GBM Anti- 
dsDNA 
1 Post infectious Low  Normal High High Not 
done 
Not 
done 
Not  
Done 
2 SLE Low  Low  Negative  Not 
Done 
High (p) Negative  High  
3 Post infectious Low  Normal Not 
done  
Negative Negative Negative Negative  
4 p-ANCA renal 
limited vasculitis 
Low  Low  Not 
done 
Not 
Done 
High (p) Negative  Not  
Done 
5 HSP Normal  Normal  Negative Negative Negative Not 
done 
Negative 
6 p-ANCA 
vasculitis 
Normal Normal   Normal  Negative  Negative  Negative Negative  
7 Post streptococcal Low  Normal   High    High  Not Done Not Done Negative  
8 IC-idiopathic Normal  Normal  Negative   High  Not done  Not Done Negative  
9 IC-idiopathic Normal  Normal  Negative    Negative  Negative  Not Done Negative  
10 IgA nephropathy Normal  Normal  Negative   Negative  Negative  Not Done Negative 
11 Post-streptococcal Low  Normal   High  High  Not done  Not Done Not  
done 
12 CGN-unspecified Normal  Normal   Negative  Negative  Negative  Negative Not  
done 
13 IC-idiopathic  Normal  Low    Negative  Negative   Not done Not Done Negative  
14 IC-idiopathic Normal  Normal   ? ? Negative  Not 
done 
Negative  
16 Post-streptococcal Normal  Normal  Negative   High  Negative  Negative Not 
done 
17 Post-streptococcal Low  Normal  Negative  High  Negative  Negative  Negative  
19 post-streptococcal Normal  Normal  High  High  Not 
done 
Not  
done  
Negative 
20 Post-streptococcal normal Normal normal High  Not  
done 
Not  
done 
Negative 
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4.3 Histopathology findings 
During the study period 2004-2015, most (80%) of the patients identified as having crescentic 
glomerulonephritis had the immune- complex mediated sub-type. Over half (11, 60%) of these children 
had a suspected post-infectious aetiology. 
 
Table 12: Aetiology of crescentic glomerulonephritis- RXH biopsy series 
Classification 
(N=24) 
Aetiology Number (%) 
Immune-complex CGN SLE 1     (4.1) 
Post-infectious 11   (46) 
HSP/IgA 2     (8.3) 
Mesangiocapillary 1     (4.1) 
Idiopathic 4     (16.6) 
Pauci-immune CGN ANCA vasculitis 2      (8.3) 
Anti-GBM CGN - 0 
CGN-unspecified - 3      (12.5) 
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Figure 8 shows below the number of cases being diagnosed with CGN has remained constant over the 
years. The average number of cases per year is two cases per year. 
 
Figure 8. Number of CGN cases by year 2004-2014 
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Table 13: Histopathology findings 
Patient 
No. 
Aetiology Light Microscope Immunofluorescence 
[N=24]  Number 
of 
glomeruli 
Percentage 
of 
Crescents 
Type of 
crescents 
Sclerosis? IgA IgG IgM C3 
1 Post infection         
2 SLE 12 100% FC No 1+ 0 <1+ 3+ 
3 Post infection 7 50% C No  0 1+ 0 1+ 
4 ANCA-vasculitis  14 50% F/FC Yes - - - - 
5 HSP 12 80% C No  3+ 0 1-
2+ 
1+ 
6 ANCA-vasculitis - 80% - No 0 2+ 1+ 2+ 
7 Post-strep 27 100% C No  - <1+ - 3+ 
8 IC-idiopathic 21 100% F  Yes  +/- 0 3+ 3+ 
9 IC-idiopathic 20 Most FC Yes  2+ 0 2+ 2+ 
10 IgA N 12 Most C/FC No  2+ 0 1+ 1/2+ 
11 Post-strep 21 100% F/FC No  0 0 0 2+ 
12 CGN-unspecified - 100% FC Yes  0 1+ 2+ 1+ 
13 IC-idiopathic 20 >50% FC Yes  3+ 2+ 1-
2+ 
1+ 
14 IC-idiopathic 14 Most  C,FC,F No  0 0 2+ 2+ 
15 Mesangiocapillary 
GN 
5 80% C  No  3+ 3+ 3+ 3+ 
16 Post-strep 6 70% FC No  0 1+ 2+ 1+ 
17 Post-strep 8 50% C  Yes  0 0 0 2-3+ 
18 Post-strep 23 Most  C  Yes - - - - 
19 Post-strep 18 80% C Yes  +/- +/- +/- 4+ 
20 Post-strep 10 50% FC Yes  3+ 0 0 2+ 
21 Post-strep 23 >50 % C Yes  0 0 0 0 
22 Pauci-immune 29  >50%  C,FC,F No  0 0 2+ 1-2+ 
23 CGN-unspecified 14 80% C Yes  0 0 2+ 1-2+ 
24 Post-strep 22 90% C Yes  1+ 0 3+ 3+ 
ANCA- anti neutrophil cytoplasmic antibodies, CGN-crescentic glomerulonephritis IC-immune complex CGN, GN-glomerulonephritis,  
 
4.5 Treatment 
Records of treatment with cyclophosphamide were available for only 18 children. The unit uses a dose 
of 500mg per meter square of body surface area. Of the 18 children whose records were available, 
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9(50%) received a single dose, 1(6%) received two doses, 5(28%) received three doses while 1 child 
received more than three doses of cyclophosphamide. Two of the children did not receive 
cyclophosphamide. 
Records of treatment with methyl-prednisone 10 mg per kilogram body weight pulses was available for 
19 patients. Only one child did not receive any methyl-prednisone. Of the patients who received methyl-
prednisone the vast majority (15, 79%) were given three doses, only 2(10.5%) got more than three doses 
and 1(5%) got one dose only. 
Records regarding initial treatment with dialysis were available for 17 children. Of these 9 (52%) 
required dialysis at initial presentation while 8 did not. Only three (15%) of the children received 
plasmapheresis and all of these had more than five sessions.  Of the three children who received 
plasmapheresis, one had systemic lupus erythematosus while two had ANCA associated vasculitis.  
 
4.6 Outcome 
Table 14. gives the renal outcome at one year. The mean follow up period was 29.9 +/- 27.3 months 
with a range of 0.5 to 72 months. A total of 24 children with CGN were seen during the period under 
review. Records were only available for 18 of these children. Of the 18 patients whose outcome records 
were available, 8(44.4%) were followed up less than 3 months, 7(38.9%) were followed up between 1 
to 5 years and only 3(16.7%) were followed up more than 5 years.  
 
Table 14: Renal outcome at one year 
 Frequency [ N=24] Percentage [%] 
Normal Renal Function   4 16.7 
CKD stage II-IV  2 8.3 
Dialysis dependant  4 16.7 
Renal transplant   2 8.3 
Followed < 1 
year because: 
not suitable  
for transplant 
 2 33.3 
Transfer out 1 
Abscond 3 
Death 1 
Diagnosed 
2015 
1   
Missing data/unknown fate 4 16.7 
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Of all the 24 children, the fate of 4 is unknown as we could not locate their records. Four (16.7%) of 
the subjects had normal renal function at one year after first presenting while 2(8.3%) still had chronic 
kidney disease after a year of follow up. Furthermore 4 (16.7%) of the patients were dialysis dependant 
while 2(16.7%) had been transplanted at one year post initial presentation. Sadly one child (4.1%) had 
died. Most of the patients on dialysis were on peritoneal dialysis. Of the 2 patients with chronic kidney 
disease one was CKD stage 5 while the other was CKD stage 2. 
There were 8 (33.3%) patients who were followed up for less than a year. Of these 2 [patient 11, patient 
12] were recognised to have ESRD at initial admission but upon assessment by the transplant committee 
were found to be unsuitable for renal replacement therapy as per hospital protocol. They were sent home 
for palliative care and a search of the health system database showed that they have had no further 
contact with the Western Cape Province health care system. They are presumed deceased.  Of the 
remaining 6 patients that were followed up for less than a year three were lost to follow up while one 
was referred back to another hospital and one died before one year had  elapsed from the time of first 
presentation. The patient who was diagnosed in 2015 was already dialysis dependant from the start. 
 Thus of the 13 patients who had been diagnosed with rapidly progressive glomerulonephritis and whose 
records were available, 10 (77%) had a poor renal or patient outcome. Based on records of last contact 
with the patients at least five (20%) of the children are known to have received a renal transplant. 
 
4.7 Association of various patient characteristics to renal outcome 
The sample size was small therefore an exact Fischer test was used to measure the strength of 
association of various patient characteristics to the renal outcome. A p value of 0.05 was considered as 
significant. The results showed two sided p values: anaemia 1.0, macroscopic haematuria 1.0, 
hypertension 0.25, sex 0.51 and nephrotic range proteinuria 1.0. Thus none had a statistically significant 
association. This is illustrated in table 14 below. 
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Table 15: Association of various patient characteristics to renal outcome 
Factor Present or not Good outcome Poor Outcome p-value* 
Sex Male 1 7 0.51 
Female 2 3 
Age < 5 years 0 1 0.63 
5-10 years 1 6 
>10 years 2 3 
Referring  
Hospital  
CTC 0 2 0.07 
WCP 3 2 
OWCP 0 6 
Time between 
start of 
symptoms and 
presentation 
< 1 week 0 4 0.07 
1-2 weeks 0 3 
>2 weeks 3 1 
Hypertension Yes  2 9 0.25 
No  1 0 
Oedema  Yes 1 9 0.11 
No 2 1 
Proteinuria Non-nephrotic 
Range  
0 2 1.00 
Nephrotic  
Range  
3 5 
Macroscopic  
Haematuria  
Yes  2 5 1.00 
No  1 4 
 
*The Fischer exact test was used to measure strength of association  
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CHAPTER 5: DISCUSSION 
 
 5.0 Incidence of crescentic glomerulonephritis 
This 10 year retrospective study was carried out to characterise the aetiology, clinical features and 
outcomes of crescentic glomerulonephritis in children presenting to a quaternary health care facility in 
Cape Town. A total of 24 cases were identified out of 470 native kidney biopsies performed during the 
study period therefore giving an incidence of 5.1 % which is similar to what has been reported 
elsewhere(14, 44). Gupta et al however reported a much lower incidence of 2.3 % of crescentic 
glomerulonephritis in their series of native kidney biopsies. Of note though is the fact that their study 
had included both children and adults and only covered a period of two years. The influence that age 
might have on the frequency of crescentic glomerulonephritis is further illustrated by an adult study 
performed in Cape Town but which showed a higher incidence of 11.3 percent over a ten year 
period(73). The number of cases of crescentic glomerulonephritis presenting per year in our series has 
not changed significantly with about two children with this entity being seen annually. 
 
5.1 Demographic and baseline characteristics of the subjects 
The mean age of the patients with crescentic glomerulonephritis was 8.3 +/- 3.4 years. The majority of 
these 11(45%) were aged 10 years and above. These findings are consistent with what has been reported  
by other investigators (25, 45, 46, 67).This age group is also the most commonly affected by classic 
post-streptococcal glomerulonephritis which accounts for quite a sizeable proportion [ 8 , 33%] of the 
children in our series(21). The mean age of the children described by Dewan et al however was higher 
at 12.2 years even though like us they had a majority of their patients presenting with immune-complex 
glomerulonephritis which was post-infectious in aetiology.  
The majority(58%) of the patients were boys and most presented in winter or spring (45) .We 
hypothesize that perhaps this could be because a sizeable number of them had a post-infectious 
aetiology and it is known that post-streptococcal glomerulonephritis is more common in boys.  Other 
series however have reported a predominance of girls (25, 67). 
We were unable to collect data on the ethnicity of the subjects because this information was not recorded 
in the patient notes. Since a significant number of the children had post-infectious glomerulonephritis 
it would have been interesting to determine whether what has been observed by other investigators 
concerning the higher frequency of post-streptococcal glomerulonephritis in black patients is true in 
this population also (13, 14, 52) . Similarly we were unable to collect data on patient living conditions 
because this information was not recorded in the notes for the majority of the children. 
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5.2 Clinical and laboratory characteristics of the patients 
The mean time that symptoms had been present before presenting to the Red Cross children’s Hospital 
was 21.4 days. In fact 60 % of the children were referred within two weeks of falling ill. This is a much 
shorter period than what was reported by dewan et al in India who had a mean of 2.4 months of 
symptoms having being present before the patients were referred. We attribute this relatively shorter 
time period in our cohort to the fact that the majority of the patients were residents of the Western Cape 
Province which has a good referral and patient transport system. It could also imply that primary health 
care providers in the catchment area of the hospital have been made aware of this entity.  
None of the children in the cohort were stunted based on height for age while two of the children were 
obese based on body mass index. As these were admission weights it is possible that the presence of 
fluid overload may have distorted the results. On the other hand the absence of stunting seems to 
supports the fact that in this cohort crescentic glomerulonephritis will often present as an acute illness. 
The most common presenting clinical features were oedema (94%), hypertension (90%), nephrotic 
range proteinuria (80%), anaemia (88%), gross haematuria (60%) and reduced renal function [GFR<15 
ml/1.73m2 /min in 50 % of those assessed]. This high prevalence of hypertension in this patient 
population has also been reported in other series (21, 44). In contrast the prevalence of hypertension 
seems to be lower in adults as illustrated by the Natal series that had included both children and 
adults(14). In fact a much earlier study by Cunningham et al also alluded to this (21). Could a possible 
explanation for this be the higher frequency of oliguria in children? The South-west Paediatric 
Nephrology study however, had a lower prevalence of hypertension (50%) and oedema in their cohort 
of 50 children(65). 
 Interestingly many of these patients had anaemia. This could reflect a dilutional anaemia secondary to 
fluid overload. Cunningham et al   also described similar findings in their cohort of patients. They found 
that 9 out of 13 of their patients had a haemoglobin less than 9 g/dl. They concluded that the anaemia 
was out of proportion to the degree of fluid overload and that the anaemia was more severe in children 
with a post-infectious aetiology. They postulated that anaemia in a patient with crescentic 
glomerulonephritis made a post infectious aetiology more likely. 
Only 3 of the 13 children for whom records were available presented with hyperkalaemia despite many 
of the children having severe renal failure. We attribute this to the fact that many of these children had 
already began receiving symptomatic management of renal failure prior to being referred. 
Of the 20 patients who had complement studies recorded in their notes, 7 had a low complement. Of 
these 1 had SLE, 1 had ANCA vasculitis and the rest were thought to have post-infectious crescentic 
glomerulonephritis. Of note is the fact that three of the children with post-streptococcal 
glomerulonephritis had a normal C3 at presentation. The diagnosis in this case was based on suggestive 
biopsy findings in the presence of anti-DNase B titres in the case of patient 16, 17 and 20 while it was 
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based on both raised ASOT and anti-DNase B in patient 19. Patient number 2 was diagnosed with SLE 
but surprisingly had raised ANCA titres. This has been described in the literature with suggestions that 
in cases of immune complex glomerulonephritis, the presence of ANCA antibodies contributes to the 
development of severe glomerular injury(2). Patient number 2 was dialysis dependant at the last contact. 
Similar to reports in the literature about the severity of renal dysfunction at initial presentation, the mean 
estimated glomerular filtration rate was 18 ml/1.73 m2 /min. Fifty percent of the patients had an 
estimated glomerular filtration rate less than 10 ml/1.73m2 /min at initial presentation. 
 
5.3. Histopathology 
Of the 24 patients with crescentic glomerulonephritis, 11(46%) had a suspected post-infectious 
aetiology mostly post-streptococcal, 8(33%). Of interest though, patient 19 had been followed up earlier 
and prior to presentation with recurrent pyelonephritis that had been associated with some renal 
dysfunction. These findings are similar to earlier reports from other parts of South Africa in both 
children and adults as well as reports from India and the United Kingdom (12-14, 44, 46).  Interestingly 
other reports from India indicate that immune-complex crescentic glomerulonephritis is less prevalent 
than the Pauci-immune subtype (25, 45, 74) . This was also the case in a nationwide survey of rapidly 
progressive glomerulonephritis that was carried out in Japan(15). One must bear in mind though the 
fact that the Japanese study included both adults and children which clearly would then distort the 
findings due to the higher prevalence of Pauci-immune crescentic glomerulonephritis in adults. An 
intriguing fact emerged from a report from northern India, which indicated that over time there had 
been a reduction in the incidence of immune-complex crescentic glomerulonephritis(45). This change 
in trends over time was also reported in the northern Indian study cited above. In the case of the northern 
Indian study there was a concomitant reduction in the cases of post-infectious glomerulonephritis which 
could account for this reduction. In fact numerous review articles have reported that there has been a 
general reduction in post-streptococcal glomerulonephritis in various regions but especially in 
industrialized nations (48-50). Based on the foregoing discussion it appears that post-infectious 
glomerulonephritis remains an important cause of crescentic glomerulonephritis in our cohort of 
patients contrary to what is being reported in other parts of the world. 
One question that begs an answer is that of what factors make certain individuals susceptible to severe 
morbidity from a usually benign disease. Like in most conditions investigators postulate that the 
genetics of the pathogen and the host may have a role to play in this. Investigators in empirical research 
have described genetic alterations in mice models in which the mice became more susceptible to 
developing crescentic glomerulonephritis. One group elucidated the central role of IL-12p40 in 
inducing the Th1 response that leads to murine crescentic glomerulonephritis. (75-77). Whether these 
identified genes would play a similarly important role in humans remains to be seen. 
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The Western Cape is known to have a high prevalence of systemic lupus erythematosus (SLE) yet 
during the ten year period under study only one patient was diagnosed with crescentic lupus nephritis.   
Feng et al conducted a study at Peking University in China that included some adolescents. They 
investigated the factors associated with developing crescentic glomerulonephritis in a population of 327 
patients with lupus nephritis. They described the presence of ANCA, high activity and chronicity scores 
on biopsy and high relapse rates as being significantly associated with crescentic lupus nephritis(78). It 
is interesting to note that our patient (number 2) did have raised ANCA titres. Though the exact role of 
ANCA has not been completely elucidated in such situations, their presence has been associated with 
more severe glomerular injury (2). Patient 2 was dialysis dependant at the last contact.It is also known 
that genetic, hormonal or ethnic factors could influence the severity and involvement of the kidney in 
SLE (79). This raises the question then of whether the lupus nephritis patients in this population may 
lack some pro-crescentic glomerulonephritis factors or alternatively whether they express protective 
factors. 
Four of the children were diagnosed as having idiopathic immune-complex crescentic 
glomerulonephritis. Thus the biopsy and serology results did not meet the criteria for any primary renal 
or secondary disease. This is similar to reports by other investigators(14).  
Not a single patient presented with anti-glomerular basement disease during the period under study. It 
is well known that this entity is rare in the paediatric age group.  In fact in one centre in the United 
States of America a 25 year retrospective review of biopsies only revealed four cases(16). 
Surprisingly, only two children were diagnosed as having had ANCA associated glomerulonephritis. 
Both of these were girls. A female predominance of ANCA associated crescentic glomerulonephritis 
has been described elsewhere(80). One patient had renal limited microscopic polyangiitis while the 
other patient presented with a vasculitic skin rash in addition to the renal dysfunction. Both girls were 
p-ANCA positive. This low incidence is consistent with literature reports from many developing 
countries. Generally reports from more industrialised counties in more recent times tend to show a 
higher prevalence of ANCA-associated glomerulonephritis.  
Also of note are the three children that appeared to have had a Pauci-immune crescentic 
glomerulonephritis but with negative serological markers. The clinical records of patient number 12 
show that both ANCA and anti-GBM antibodies were negative at presentation. This state of affairs has 
been described before and is referred to as ANCA-negative Pauci-immune crescentic 
glomerulonephritis(22). This entity is characterised by a paucity of immune deposits on biopsy and a 
persistent absence of ANCA antibodies in the serum and is said to be present in between 10 to 30 percent 
of patients who have Pauci-immune crescentic glomerulonephritis(2, 22). Patients reportedly have 
fewer extra-renal manifestations of disease and investigators postulate that neutrophils are central to the 
pathogenesis of the condition(22). Earlier Jeanette had postulated that this state of persistent ANCA 
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being seronegative could be explained by the fact that other types of antibodies against neutrophil 
cytoplasmic antigens were responsible for the glomerular damage but that they were undetectable with 
the assays in use then(1). Indeed some reports suggest that lysosomal membrane protein 2 [LAMP-2], 
a novel ANCA subtype, is present in almost all patients with active untreated ANCA associated 
vasculitis (81). However other studies such as the one by Roth et al in 2012 found that LAMP-2 was 
not prevalent in patients with ANCA vasculitis and thus did not support a mechanistic relationship 
between it and ANCA vasculitis(82). A recent review by  Kain et al addresses this controversy(83). 
 
Most of the patients had histology that showed greater than 80% involvement of glomeruli with most 
of the crescents being either cellular or fibro-cellular. It was quite surprising that most of the children 
had such a high percentage of involved glomeruli despite reasonably quick referral and treatment. A 
similar phenomena was reported by Almera-Borja et al in the Philippines(67). Numerous studies have 
shown an association between poor renal outcome and a higher percentage of involved glomeruli and a 
high percentage of fibro-cellular crescents (18, 44). Jardim et al had a cohort of 30 patients but they did 
not demonstrate a correlation between percentage of involved glomeruli and renal outcome(51). 
Perhaps further strategies need to be put in place to sensitize primary level health workers about this 
renal syndrome and the absolute need for speedy nephrology referral in order to improve renal 
outcomes. 
 
5.4 Treatment 
The health referral system in South Africa is quite well developed with far flung medical workers being 
able to discuss patients with a renal consultant telephonically. This was reflected by the fact that many 
of the children in our series had in fact already received a dose of methyl-prednisone even before arrival. 
All the children received at least three doses of steroids intravenously. 
Of the 18 children whose treatment charts available, 16 received at least one dose of cyclophosphamide. 
Among these were 11 with a suspected post-infectious aetiology. There is no consensus on the use of 
cyclophosphamide in the management of post-infectious crescentic glomerulonephritis (31, 84, 85). 
Nine (52%) of the children received acute dialysis. 
Most of the patients on dialysis were on peritoneal dialysis. Of the 3 patients with chronic kidney disease 
two of the children were stage 5 while one child was stage 2. 
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5.5 Renal outcome 
Only 13 patients were followed up for at least one year. Because the Red Cross Children’s Hospital is 
a referral centre, eight patients were sent back to their home centres for continued follow up after initial 
stabilisation. Of the children followed up for at least a year 10 (77 %) had what could be described as a 
poor outcome (CKD-3, dialysis dependant-3, transplant-2, death-1). This bleak outcome is similar to 
earlier studies from South Africa and other countries (12-14, 44, 51, 66) . And like the earlier studies 
from South Africa, a post-infectious aetiology continues to play a major role in the disease morbidity. 
Of the patients sent to other hospitals for continued, care 2 were recognized to be in need of long term 
renal replacement therapy but this had been withheld due to the children’s poor social circumstances. 
This highlights the fact that in resource poor regions many children do not have access to the expensive 
renal replacement therapies and that as far as possible preventable causes of end stage renal disease, 
like crescentic glomerulonephritis should be recognised early and prompt treatment should be 
instituted(5, 8). 
Thus by one year post the diagnosis of rapidly progressive glomerulonephritis 10 (77%) of the 13 
children whose records were available can be said to have had a poor renal or patient outcome while as 
at the last contact with the patients at least five (20%) of the all the children in the cohort are known to 
have received a renal transplant. 
5.6. Correlation of various patient characteristics with renal outcome 
The sample size was small therefore an exact Fischer test was used to measure the strength of 
association of various patient characteristics to the renal outcome. A p value of 0.05 was considered as 
significant. The results showed two sided p values: anaemia 1.0, macroscopic haematuria 1.0, 
hypertension 0.25, sex 0.51 and nephrotic range proteinuria 1.0. Thus none had a statistically significant 
association. In contrast other series have noted a correlation between presence of hypertension, 
nephrotic range proteinuria and the percentage of fibrous crescents with poor renal survival.(18, 44, 46, 
86). Other  
In summary then, crescentic glomerulonephritis in our biopsy series occurs primarily in children older 
than five years who are predominantly boys with a post-infectious aetiology in a large proportion. The 
level of poor renal outcome remains inordinately high despite quite reasonable speed of referral as well 
as administration of widely accepted therapies. There remains a need to better characterise some of the 
factors that may result in severe glomerular damage in children with post-infectious glomerulonephritis 
in this population. 
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CHAPTER 6 
 
6.0 Conclusion 
We conclude that the incidence of crescentic glomerulonephritis in the series of native kidney biopsies 
performed at the Red Cross Children’s Hospital in the period 2004 to June 2015 was 5.1%. The most 
common sub-type is the immune-complex crescentic glomerulonephritis with a post-infectious cause 
being the leading aetiology. Renal outcome remains poor in about 77 percent of affected children, 
despite reasonably quick referral of patients and appropriate therapy. More needs to be done to reduce 
the time that it takes for patients to be seen by a nephrologist even further. In addition we were unable 
to prove any statistically significant correlation between the patient clinical features and outcomes 
perhaps due to the small sample size involved. Going forward, it may be prudent to begin a multi-centre 
prospective national registry to try and collect standardized patient data as well as possibly explore any 
genetic or immunological factors that may contribute to this severe presentation of post-infectious 
glomerulonephritis. 
 
6.1 Recommendations 
 
1. Paediatric nephrologists need to increase the awareness of primary health care providers 
concerning the presentation of rapidly progressive glomerulonephritis emphasising the need for 
prompt involvement of a nephrologist in patient care. 
2. Crescentic glomerulonephritis is a rare entity. Thus it may be prudent for nephrologists to 
collaborate and establish a multicentre prospective registry that will have sufficient subjects so 
as to better describe the outcomes and their determinants and possibly explore how genetics 
may influence severity in the various conditions that can lead to crescentic glomerulonephritis 
in this population. 
 
6.2 Study limitations 
1. This was a retrospective folder review thus some data was not obtained because it had not 
been recorded in the notes. In addition the number of subjects was small thus no firm 
conclusions regarding associations can be drawn from the data. 
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APPENDIX A:  STUDY PROFORMA 
Hospital number   : 
Subject study number:   
Date of presentation to RXCWMH: 
 
Part I: Demographics 
1. Age (DOB)                                          . . . . . . . . . . . . . . . . . . . . . . . 
 
2.  Sex                                                     1) Male       2) Female 
 
 
 
3. Race                                              1) Black   2) Coloured   3) Indian     4) White     5)Other 
 
4. Referring Hospital                         . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
 
 
5. Number of people in the home          . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
6. Number of rooms in the house         . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
7. Socioeconomic Class                      1) H1           2)  H2        3) H3 
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Part II: clinical data 
 
8. Age at diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
9. Height . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
 
10. Weight  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
11.  BMI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
12. Presenting symptoms 
i. Headache                   1) Yes           2) No 
ii. Cough                         1)  Yes          2) No 
iii. Haemoptysis                1) Yes          2) No 
iv. Vasculitic rash             1) yes           2) No 
v. Odema                          1) Yes          2) No 
vi. Seizures                        1)  Yes         2) No 
vii. Arthritis                        1)  Yes         2) No 
viii. Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
13. Duration of symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
14. Hypertension                                  1) Yes         2) No 
 
 
 
15. Blood pressure at presentation . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
 
16. Blood pressure at last follow-up(date) . . . . . . . . . . . . . . . . . . . . . 
 
 
 
17. Protein /creatinine ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
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18. Haematuria . . .  . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
19. Plasmapheresis     1) Yes       2) No 
                                          If Yes, number of sessions …………… 
                                                       Date first session . . . . . . . . . . .  
 
20. Methyl prednisone  1) Yes     2) No 
                                             If Yes, number of doses . . . . . . . . . . . . . . . 
                                                          Date first dose . . . . . . . . . . . . . . . . . 
21. Cyclophosphamide  1) Yes       2) No 
                                 If Yes, number of doses . . . . . . . . . . . . . . 
                                     Date first dose . . . . . . . . . . . . . . . . . . . .   
 
22. Maintenance drug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
23. Duration of follow-up (months) . . . . . . . . . .   . . . . .. . . . . . . .  .  
 
 
 
24. Outcome at one year   a) eGFR . . .  . . . . . . . 
                                    b) CKD stage . . . .  . . . . . . 
                                    c) Haemodialysis dependant   1) Yes     2) No 
                                    d) Peritoneal Dialysis      1) Yes    2) No 
                                    e) Renal Transplant           1) Yes    2) No 
                                   f) Death                               1) Yes     2) No 
                                   g) lost to followup               1) Yes      2) No 
 
                                      
1 
 
Part III: Laboratory data 
 
25. FBC at presentation 
a. Hb . . . . . . . . .  
b. WBC . . . . . . . 
c. Plt . . . . . . . . . . 
d. ESR . . . . . . . . . .. 
 
26. Electrolytes/Urea/Creatinine at presentation 
a. Na . . . . . .. . 
b. K . . . . . . . . 
c. Cl . . . . . . . . 
d. Ca . . . . . . . . 
e. Mg . . . . . . . .  
f. iPO4 . . . . . . . 
g. Ur . . . . . . . .  
h. Cr . . . . . . . .  
 
27. Peak Creatinine (date) . . . . . . . . . . . . . . . . . . . . 
 
28. Creatinine at one Year . . . . . . . . . . . . . . . . . . . . 
 
29. Creatinine at last follow-up . . . . . . . . . . . . . . . .  
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30. Autoimmune markers  
 
                                                         Value                      Interpretation 
a. CRP                                                    1) High   2) Low  3) Normal   4) Not done  
b. ANA                                                   1)high  2)Low  3) Normal    4) not done  
c. Anti Dnase B                                      1) high     2) Low  3) Normal        4) not done 
d. pANCA                                              1) high   2) Low   3)normal   4) not done 
e. cANCA                                               1) high  2) low   3)normal  4) not done 
f. Anti- GBM antibodies                        1)high   2)low      3)normal     4) not done 
g. C3                                                        1)High  2) Low    3) Normal       4) Not done 
h. C4                                                          1) High   2) Low     3) Normal     4) Not done 
i. Anti-ds DNA                                        1) High  2) Low      3) Normal      4) Not done 
 
 
31. HIV status 
1) Positive    2) Negative    3) Not done 
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Part IV: HISTOPATHOLOGY DATA SHEET                                                                                                                          
Subject study number . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Subject hospital number . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Date specimen collected . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
Light Microscopy 
 
32.  Crescentic glomerulonephritis        1) Yes               2) No 
 
33.  Number of glomeruli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
34.  Proportion of glomeruli with crescents . . . . . . . . . . . . . .  . 
 
35. Proportion of fibrocellular crescents . . . . . . . . . . . . . . . . . .  
 
36. Proportion of cellular crescents . . . . . . . . . . . . . . . . . . . . . . 
 
37.  Proportion  of fibrinous crescents . . . . . . . . . . . . . . . . . . . . . 
 
38. Presence  tuft necrosis                   1) Yes                2) No 
 
39. Presence of rupture of Bowman’s capsule  1) Yes     2) No 
 
40. Presence of fibrinoid necrosis . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
41. Degree of interstitial fibrosis . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
42. Degree of tubular atrophy . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 
43. Degree of arteriolar fibrin deposition . . . . . . . . . . . . . . . . . . . .  
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Immunoflourescence 
 
44.    Immunoglobulins  
i. IgA 1) yes    2) No 
ii. Ig M          1) Yes   2) No 
iii. IgG            1) Yes   2) No 
 
45. Complement  
i. C 1q           1) yes        2) No 
ii. C3              1) Yes       2) No 
iii. C4              1) Yes       2) No 
iv. Other.Specify. . . . . . . . . . . . .  
 
            Electron Microscopy 
46. Podocyte effacement   1) Yes              2) No   
47. Subendothelial deposits  1) Yes    2) No 
48. Subepithelial deposits      1) Yes    2) No 
49. Other, Specify . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
                   
 
Conclusion . . . . . . . . . . . . . . . . . . . . . . . 
 
Signature 
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APPENDIX B: HOSPITAL APPROVAL OF RESEARCH 
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APPENDIX C: ETHICS APPROVAL LETTER 
